The European Medicines Agency has taken issue with an analysis published in the British Medical Journal that questioned the growing enthusiasm for the use of observational real-world data (RWD) as a basis for regulatory, clinical and health policy decision making.
The analysis, by authors from Germany’s Institute for Quality and Efficiency in Health Care (IQWiG) and the Belgian health...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?